Alan J. Dalby

Nessuna posizione attualmente

Health Technology

Consumer Non-Durables

Profilo

Alan Dalby became a Non-executive Director of Acambis on 1 May 1998.
He was an executive director of SmithKline, a predecessor company to GlaxoSmithKline plc, and retired from the role of Chairman of Reckitt Benckiser plc in 2001.
He is a director of Alteon, Inc., a US-based biotechnology company.
He is the senior independent Non-executive Director.
The Board considers Mr Dalby to be an independent Non-executive Director.
He is a member of the Audit Committee and Nominations Committee, and Chairman of the Remuneration Committee.

Precedenti posizioni note di Alan J. Dalby

Società	Posizione	Fine
Acambis Plc Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK.	Direttore/Membro del Consiglio	22/09/2008
RECKITT BENCKISER GROUP PLC	Presidente	01/01/2001
Smithkline Beecham Plc Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.	Direttore/Membro del Consiglio	-
SYNVISTA THERAPEUTICS, INC.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Alan J. Dalby

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private